Common use of Hodnotený liek Clause in Contracts

Hodnotený liek. (i) Institution acknowledges that the Compound is owned or controlled by Gilead and that neither the terms of this Agreement nor the Protocol, nor any activities conducted by Institution for the Trial, shall be construed to grant to Institution any rights in or to the Compound. (i) Inštitúcia potvrdzuje, že zlúčenina je vlastníctvom alebo je pod výkonom kontroly spoločnosti Gilead a žiadna z podmienok tejto Zmluvy ani Protokolu, ani žiadne činnosti vykonávané Inštitúciou v súvislosti s Klinickým skúšaním nebudú vykladané tak, aby Inštitúcii poskytovali akékoľvek práva na Zlúčeninu. (ii) Except as otherwise agreed by the Parties, Gilead will provide the Compound and any control/placebo materials administered to Trial subjects as part of the Trial (collectively, the “Trial Drug”) free of charge to Institution or Investigator for administering or dispensing solely by or under the supervision of Investigator or sub- investigators to Trial subjects at the Trial Site in strict compliance with the Protocol. Gilead or its designee undertakes to deliver the Trial Drug directly tothe hospital pharmacy of the Institution. Institution will ensure delivery of Trial Drug to the Investigator, to allow him to conduct the Trial in compliance with the Agreement and the Protocol. Institution and Investigator undertake to handle the Trial Drug in accordance with instructions provided by Gilead and use it in the manner described in the Protocol. Gilead undertakes to provide free of charge Study related training of the delegated Trial Personnel member. (ii) Pokiaľ sa Zmluvné strany nedohodnú inak, spoločnosť Gilead zdarma poskytne Inštitúcii alebo Skúšajúcemu Zlúčeninu a všetky kontrolné/placebo materiály podávané účastníkom Klinického skúšania v rámci Klinického skúšania (ďalej len súhrnne (iii) Institution shall not use the Trial Drug for any purpose other than as required to conduct the Trial in strict compliance with the Protocol. Institution shall not transfer the Trial

Hodnotený liek. (i) Institution acknowledges that the Compound is owned or controlled by Gilead and that neither the terms of this Agreement nor the Protocol, nor any activities conducted by Institution for the Trial, shall be construed to grant to Institution any rights in or to the Compound. (i) Inštitúcia potvrdzuje, že zlúčenina je vlastníctvom alebo je pod výkonom kontroly spoločnosti Gilead a žiadna z podmienok tejto Zmluvy ani Protokolu, ani žiadne činnosti vykonávané Inštitúciou v súvislosti s Klinickým skúšaním nebudú vykladané tak, aby Inštitúcii poskytovali akékoľvek práva na Zlúčeninu. (ii) Except as otherwise agreed by the Parties, Gilead will provide the Compound and any control/placebo materials administered to Trial subjects as part of the Trial (collectively, the “Trial Drug”) free of charge to Institution or Investigator for administering or dispensing solely by or under the supervision of Investigator or sub- investigators to Trial subjects at the Trial Site in strict compliance with the Protocol. Gilead or its designee undertakes to deliver the Trial Drug directly tothe hospital pharmacy of the Institution. Institution will ensure delivery of Trial Drug to the Investigator, to allow him to conduct the Trial in compliance with the Agreement and the Protocol. Institution and Investigator undertake to handle the Trial Drug in accordance with instructions provided by Gilead and use it in the manner described in the Protocol. Gilead undertakes to provide free of charge Study related training of the delegated Trial Personnel member.Trial (ii) Pokiaľ sa Zmluvné strany nedohodnú inak, spoločnosť Gilead zdarma poskytne Inštitúcii alebo Skúšajúcemu Zlúčeninu a všetky kontrolné/placebo materiály podávané účastníkom Klinického skúšania v rámci Klinického skúšania (ďalej len súhrnne (iii) Institution shall not use the Trial Drug for any purpose other than as required to conduct the Trial in strict compliance with the Protocol. Institution shall not transfer the TrialTrial Drug to any third parties. Institution shall handle, store, ship and dispose of the Trial Drug as directed by Gilead or its designee and in compliance with all applicable laws, rules, and regulations.

Hodnotený liek. (i) Institution acknowledges that the Compound is owned or controlled by Gilead and that neither the terms of this Agreement nor the Protocol, nor any activities conducted by Institution for the Trial, shall be construed to grant to Institution any rights in or to the Compound. (i) Inštitúcia potvrdzuje, že zlúčenina je vlastníctvom alebo je pod výkonom kontroly spoločnosti Gilead a žiadna z podmienok tejto Zmluvy ani Protokolu, ani žiadne činnosti vykonávané Inštitúciou v súvislosti s Klinickým skúšaním nebudú vykladané tak, aby Inštitúcii poskytovali akékoľvek práva na Zlúčeninu. (ii) Except as otherwise agreed by the Parties, Gilead will provide the Compound and any control/placebo materials administered to Trial subjects as part of the Trial (collectively, the “Trial Drug”) free of charge to Institution or Investigator for administering or dispensing solely by or under the supervision of Investigator or sub- investigators to Trial subjects at the Trial Site in strict compliance with the Protocol. Gilead or its designee undertakes to deliver the Trial Drug directly tothe hospital pharmacy of the Institution. Institution will ensure delivery of Trial Drug to the Investigator, to allow him to conduct the Trial in compliance with the Agreement and the Protocol. Institution and Investigator undertake to handle the Trial Drug in accordance with instructions provided by Gilead and use it in the manner described in the Protocol. Gilead undertakes to provide free of charge Study related training of the delegated Trial Personnel member. (ii) Pokiaľ sa Zmluvné strany nedohodnú inak, spoločnosť Gilead zdarma poskytne Inštitúcii alebo Skúšajúcemu Zlúčeninu a všetky kontrolné/placebo materiály podávané účastníkom Klinického skúšania v rámci Klinického skúšania (ďalej len súhrnne (iii) Institution shall not use the Trial Drug for any purpose other than as required to conduct the Trial in strict compliance with the Protocol. Institution shall not transfer the TrialTrial Drug to any third parties. Institution shall handle,

Hodnotený liek. (i) Institution acknowledges that the Compound is owned or controlled by Gilead and that neither the terms of this Agreement nor the Protocol, nor any activities conducted by Institution for the Trial, shall be construed to grant to Institution any rights in or to the Compound. (i) Inštitúcia potvrdzuje, že zlúčenina je vlastníctvom alebo je pod výkonom kontroly spoločnosti Gilead a žiadna z podmienok tejto Zmluvy ani Protokolu, ani žiadne činnosti vykonávané Inštitúciou v súvislosti s Klinickým skúšaním nebudú vykladané tak, aby Inštitúcii poskytovali akékoľvek práva na Zlúčeninu. (ii) Except as otherwise agreed by the Parties, Gilead will provide the Compound and any control/placebo materials administered to Trial subjects as part of the Trial (collectively, the “Trial Drug”) free of charge to Institution or Investigator for administering or dispensing solely by or under the supervision of Investigator or sub- investigators to Trial subjects at the Trial Site in strict compliance with the Protocol. Gilead or its designee undertakes to deliver the Trial Drug directly tothe hospital pharmacy of the Institution. Institution will ensure delivery of Trial Drug to the Investigator, to allow him to conduct the Trial in compliance with the Agreement and the Protocol. Institution and Investigator undertake to handle the Trial Drug in accordance with instructions provided by Gilead and use it in the manner described in the Protocol. Gilead undertakes to provide free of charge Study related training of the delegated Trial Personnel member. (ii) Pokiaľ sa Zmluvné strany nedohodnú inak, spoločnosť Gilead zdarma poskytne Inštitúcii alebo Skúšajúcemu Zlúčeninu a všetky kontrolné/placebo materiály podávané účastníkom Klinického skúšania v rámci Klinického skúšania (ďalej len súhrnne (iii) Institution shall not use the Trial Drug for any purpose other than as required to conduct the Trial in strict compliance with the Protocol. Institution shall not transfer the TrialTrial Drug to any third parties. Institution shall handle, store, ship and dispose of the Trial Drug as directed by Gilead or its designee and in compliance with